Michael Weller
Impact in
- Genetics top 0.01%
- Glioma Diagnosis and Treatment
- Cancer Research top 0.01%
- Cancer, Hypoxia, and Metabolism
- MicroRNA in disease regulation
Papers in
- Co-authors
- Wolfgang Wick (181 shared papers)Roger Stupp (73 shared papers)Martin J. van den Bent (72 shared papers)Thierry Gorlia (46 shared papers)Warren P. Mason (13 shared papers)R.O. Mirimanoff (7 shared papers)John Gregory Cairncross (6 shared papers)Robert Charles Janzer (2 shared papers)
- Journals
- Neuro-Oncology (204 papers)Acta Neuropathologica (49 papers)Journal of Neuro-Oncology (46 papers)The Lancet Oncology (33 papers)Neurology (33 papers)
- Partner nations
- GermanySwitzerlandUnited States
In The Last Decade
Michael Weller
1.3k papers receiving 129.0k citations
Michael Weller's Hit Papers
Peers
Comparison fields: 5 of 213
- Genetics 60.3k
- Cancer Research 19.6k
- Neurology 12.6k
- Oncology 18.8k
- Immunology 14.2k
Countries citing papers authored by Michael Weller
This map shows the geographic impact of Michael Weller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Weller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Weller more than expected).
Fields of papers citing papers by Michael Weller
This network shows the impact of papers produced by Michael Weller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Weller. The network helps show where Michael Weller may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Weller, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 1.4k papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma Hit paper breakdown → | 2005 | 17738 |
| 2 | Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Hit paper breakdown → | 2009 | 6545 |
| 3 | MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma Hit paper breakdown → | 2005 | 5960 |
| 4 | DNA methylation-based classification of central nervous system tumours Hit paper breakdown → | 2018 | 2183 |
| 5 | Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma Hit paper breakdown → | 2017 | 2013 |
| 6 | An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor Hit paper breakdown → | 2011 | 1605 |
| 7 | EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood Hit paper breakdown → | 2020 | 1327 |
| 8 | Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma Hit paper breakdown → | 2020 | 1136 |
| 9 | Current state of immunotherapy for glioblastoma Hit paper breakdown → | 2018 | 1075 |
| 10 | Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas Hit paper breakdown → | 2009 | 991 |
| 11 | Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial Hit paper breakdown → | 2017 | 930 |
| 12 | Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial Hit paper breakdown → | 2012 | 908 |
| 13 | Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions Hit paper breakdown → | 2020 | 877 |
| 14 | European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas Hit paper breakdown → | 2017 | 873 |
| 15 | Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial Hit paper breakdown → | 2014 | 872 |
| 16 | Glioma Hit paper breakdown → | 2015 | 871 |
| 17 | Lomustine and Bevacizumab in Progressive Glioblastoma Hit paper breakdown → | 2017 | 742 |
| 18 | 2007 | 720 | |
| 19 | Correlation of O 6 -Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity Hit paper breakdown → | 2008 | 705 |
| 20 | Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas Hit paper breakdown → | 2010 | 690 |
About Michael Weller
Michael Weller is a scholar working on Genetics, Neurology, Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 1.4k papers that have together received 132.0k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (564 papers), Brain Metastases and Treatment (162 papers), Cell death mechanisms and regulation (92 papers), Meningioma and schwannoma management (75 papers), CNS Lymphoma Diagnosis and Treatment (57 papers), Immunotherapy and Immune Responses (55 papers), Cell Adhesion Molecules Research (52 papers) and Cancer, Hypoxia, and Metabolism (48 papers). The work is most often cited by research in Genetics (60.3k citations), Cancer Research (19.6k citations), Neurology (12.6k citations), Oncology (18.8k citations) and Immunology (14.2k citations). Michael Weller has collaborated with scholars based in Germany, Switzerland and United States. Frequent co-authors include Wolfgang Wick, Roger Stupp, Martin J. van den Bent, Thierry Gorlia, Warren P. Mason, R.O. Mirimanoff, John Gregory Cairncross, Robert Charles Janzer, Guido Reifenberger and Alba Ariela Brandes. Their work appears in journals such as Neuro-Oncology, Acta Neuropathologica, Journal of Neuro-Oncology, The Lancet Oncology and Neurology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.